Volume 24, Number 11—November 2018
Racial/Ethnic Disparities in Antimicrobial Drug Use, United States, 2014–2015
Highlight and copy the desired format.
|EID||Olesen SW, Grad YH. Racial/Ethnic Disparities in Antimicrobial Drug Use, United States, 2014–2015. Emerg Infect Dis. 2018;24(11):2126-2128. https://dx.doi.org/10.3201/eid2411.180762|
|AMA||Olesen SW, Grad YH. Racial/Ethnic Disparities in Antimicrobial Drug Use, United States, 2014–2015. Emerging Infectious Diseases. 2018;24(11):2126-2128. doi:10.3201/eid2411.180762.|
|APA||Olesen, S. W., & Grad, Y. H. (2018). Racial/Ethnic Disparities in Antimicrobial Drug Use, United States, 2014–2015. Emerging Infectious Diseases, 24(11), 2126-2128. https://dx.doi.org/10.3201/eid2411.180762.|
Using a US nationwide survey, we measured disparities in antimicrobial drug acquisition by race/ethnicity for 2014–2015. White persons reported twice as many antimicrobial drug prescription fills per capita as persons of other race/ethnicities. Characterizing antimicrobial drug use by demographic might improve antimicrobial drug stewardship and help address antimicrobial drug resistance.
Antimicrobial drug use varies by sex, age, and geography (1), and antimicrobial drug prescribing practice for specific medical conditions and age cohorts varies by patients’ race/ethnicity (2–4). Many studies on the role of patient race/ethnicity in antimicrobial drug prescribing practice focus on acute respiratory illnesses because antimicrobial drugs are often inappropriately prescribed for these conditions. The subjective diagnostic criteria for respiratory illnesses might result in race/ethnicity influencing prescribing practice more for these illnesses than for other illnesses (4). Despite our increasing knowledge of the role of patient race/ethnicity in drug prescribing practice for specific conditions, how or whether these specific effects translate into overall antimicrobial drug use by race/ethnicity remains unclear. In this report, we address this gap in knowledge by describing the extent of racial/ethnic disparities in overall antimicrobial drug prescription fill rates in the United States.
We used the nationwide Medical Expenditure Panel Survey (MEPS) to acquire data about race/ethnicity and outpatient antimicrobial drug use for 2014–2015, the latest years with data available. MEPS contains data on members of a nationally representative sample of households (5,6). A person’s race/ethnicity is reported by the respondent and imputed in <0.1% of cases. Information about race and Hispanic ethnicity are collected in separate questions. Data regarding prescriptions filled at outpatient pharmacies are collected from the respondent and, if the respondent approves, verified with the filling pharmacy. Data are afterward cross-referenced and cleaned by survey preparers (5).
We used 2 exposure variables. The first was a categorical race/ethnicity variable with 5 values: Hispanic, non-Hispanic white only, non-Hispanic black only, non-Hispanic Asian only, and non-Hispanic other or multiple race. The second exposure variable was dichotomous and indicated whether white was the race or 1 of the races of the respondent. This exposure variable included all persons from the non-Hispanic white category, some from the Hispanic category, and some from the other or multiple race category. The main outcome was reported outpatient antimicrobial drug prescription fills per 1,000 persons per year stratified by major antimicrobial drug class (penicillins, macrolides, quinolones, sulfonamides, other). The complex survey design was accounted for when computing rates and CIs with survey package version 3.32 in R version 3.4.1 (Technical Appendix).
The reported annual outpatient prescription fill rate for all antimicrobial drugs was 373 (95% CI 358–388) fills/1,000 persons. This rate varied by race/ethnicity; non-Hispanic whites reported the highest rate, followed by persons of other or multiple race/ethnicity, Hispanics, non-Hispanic blacks, and non-Hispanic Asians (Figure, panel A). White persons reported 2.0 (95% CI 1.9–2.2)–fold more fills per capita than nonwhite persons (Figure, panel B). The reported fill rate disparity was similar for macrolides (2.0 [95% CI 1.8–2.4]–fold higher), sulfonamides (2.2 [95% CI 1.8–2.7]–fold higher), and quinolones (2.3 [95% CI 1.9–2.8]–fold higher) but smaller for penicillins (64% [95% CI 48%–82%] higher).
We found a large disparity in antimicrobial drug fill rates by race/ethnicity: white persons reported making twice as many antimicrobial drug prescription fills as persons who were not white. Disparities were apparent for each major antimicrobial drug class, rather than different drug classes being used more predominantly by persons of particular race/ethnicities.
This study is subject to several limitations. First, the survey is not a perfect measure of antimicrobial drug use. Survey respondents report medications they remember filling, subjecting results to systematic differences in respondents’ abilities to recall medications (6). Survey preparers then obtain information about those medications from the pharmacies the respondents visited, which themselves might have systematic differences in completeness of records (5). Also, respondents might not have complete information about other household members’ antimicrobial drug use or might choose not to disclose all antimicrobial drug use. Second, nonprescription antimicrobial drug use might be higher among minority groups (7), perhaps mitigating the observed disparity. Last, the survey measures reported antimicrobial drug fills and not actual use (8); the fill rates we report are substantially lower than those measured by others using sales data (1) or other national surveys (9).
Whether differences in antimicrobial drug use and race/ethnicity lead to disparities in antimicrobial drug resistance is unclear. We expect that disparities in use, regardless of their cause, will lead to disparities in the proportions of carried bacteria that are antimicrobial drug–resistant. Absolute rates of antimicrobial drug–resistant infections, however, might follow different patterns (10). For example, higher macrolide use among white persons might lead to macrolide resistance in a greater proportion of Streptococcus pneumoniae bacteria carried by whites, but if white persons have fewer S. pneumoniae infections, then they would incur a lower absolute rate of macrolide-resistant S. pneumoniae infections. Further studies comparing antimicrobial drug use, antimicrobial drug resistance, and disease prevalence by race/ethnicity will be critical for addressing this question and improving antimicrobial drug stewardship.
Dr. Olesen is a postdoctoral fellow at the Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA. His research interests include antimicrobial drug use and resistance. Dr. Grad is the Melvin J. and Geraldine L. Glimcher Assistant Professor of Immunology and Infectious Diseases at the Harvard T.H. Chan School of Public Health. His research interests include antimicrobial drug use and resistance and the evolution and spread of pathogens.
S.W.O. was supported by cooperative agreement U54GM088558 from the National Institute of General Medical Sciences.
- Hicks LA, Bartoces MG, Roberts RM, Suda KJ, Hunkler RJ, Taylor TH Jr, et al. US outpatient antibiotic prescribing variation according to geography, patient population, and provider specialty in 2011. Clin Infect Dis. 2015;60:1308–16.
- Goyal MK, Johnson TJ, Chamberlain JM, Casper TC, Simmons T, Alessandrini EA, et al.; Pediatric Care Applied Research Network (PECARN). Racial and ethnic differences in antibiotic use for viral illness in emergency departments. Pediatrics. 2017;140:e20170203.
- Steinman MA, Landefeld CS, Gonzales R. Predictors of broad-spectrum antibiotic prescribing for acute respiratory tract infections in adult primary care. JAMA. 2003;289:719–25.
- Gerber JS, Prasad PA, Localio AR, Fiks AG, Grundmeier RW, Bell LM, et al. Racial differences in antibiotic prescribing by primary care pediatricians. Pediatrics. 2013;131:677–84.
- Hill SC, Roemer M, Stagnitti MN. Methodology report #29. Outpatient prescription drugs: data collection and editing in the 2011 medical expenditure panel survey. 2014 Mar [cited 2018 May 7]. https://meps.ahrq.gov/data_files/publications/mr29/mr29.shtml
- Hill SC, Zuvekas SH, Zodet MW. Implications of the accuracy of MEPS prescription drug data for health services research. Inquiry. 2011;48:242–59.
- Zoorob R, Grigoryan L, Nash S, Trautner BW. Nonprescription antimicrobial use in a primary care population in the United States. Antimicrob Agents Chemother. 2016;60:5527–32.
- Tamblyn R, Eguale T, Huang A, Winslade N, Doran P. The incidence and determinants of primary nonadherence with prescribed medication in primary care: a cohort study. Ann Intern Med. 2014;160:441–50.
- Fleming-Dutra KE, Hersh AL, Shapiro DJ, Bartoces M, Enns EA, File TM Jr, et al. Prevalence of inappropriate antibiotic prescriptions among US ambulatory care visits, 2010–2011. JAMA. 2016;315:1864–73.
- Kanjilal S, Sater MRA, Thayer M, Lagoudas GK, Kim S, Blainey PC, et al. Trends in antibiotic susceptibility in Staphylococcus aureus in Boston, Massachusetts, from 2000 to 2014. J Clin Microbiol. 2017;56:e01160-17.
FigureCite This Article
Original Publication Date: 9/27/2018
- Page created: October 17, 2018
- Page last updated: October 17, 2018
- Page last reviewed: October 17, 2018
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)